CYP11B2-IN-1
Modify Date: 2025-08-27 14:55:44
CYP11B2-IN-1 structure
|
Common Name | CYP11B2-IN-1 | ||
|---|---|---|---|---|
| CAS Number | 1356479-78-1 | Molecular Weight | 311.35 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C18H18FN3O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CYP11B2-IN-1CYP11B2-IN-1 is a CYP11B2 inhibitor with an IC50 of 2.3 nM. CYP11B2-IN-1 inhibits CYP11B1 with an IC50 of 142 nM[1]. |
| Name | CYP11B2-IN-1 |
|---|
| Description | CYP11B2-IN-1 is a CYP11B2 inhibitor with an IC50 of 2.3 nM. CYP11B2-IN-1 inhibits CYP11B1 with an IC50 of 142 nM[1]. |
|---|---|
| Related Catalog | |
| Target |
CYP11B2:2.3 nM (IC50) CYP11B1:142 nM (IC50) |
| In Vitro | CYP11B2-IN-1 (Compound 32) also inhibits CYP19 with an IC50 of 1021 nM [1] 。 |
| In Vivo | In a rhesus pharmacodynamic model, CYP11B2-IN-1 (Compound 32) produces dose-dependent aldosterone lowering efficacy, with no apparent effect on cortisol levels[1]. CYP11B2-IN-1also displays a good rhesus pharmacokinetics profile, with low plasma clearance and acceptable oral exposure.When dosed i.v. at 0.01 and 0.3 mg/kg, CYP11B2-IN-1 produces reductions in aldosterone AUC of 62% and 95%, respectively, compared to baseline[1]. |
| References |
| Molecular Formula | C18H18FN3O |
|---|---|
| Molecular Weight | 311.35 |
| InChIKey | OAMLIJKKGZLNHE-UHFFFAOYSA-N |
| SMILES | CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1 |